



➤ **[COVID-19 rapid guideline: managing COVID-19- guidance \(NG191\)](#)**

This living guideline brings together existing recommendations on managing COVID-19 so that healthcare staff and those planning and delivering services can find and use them more easily, and includes new recommendations on therapeutics.

➤ **[Interim Position Statement: Inhaled budesonide for adults \(50 years and over\) with COVID-19](#)**

The PRINCIPLE trial has reported a 3-day median benefit in self-reported recovery for patients with COVID-19 in the community setting who received inhaled budesonide. The impact on hospitalisation rates or mortality has not been established, but the evaluation is ongoing, so recommendations may change as more data become available. At this point in time, inhaled budesonide is not being recommended for routine use, but can be considered to be prescribed by healthcare professionals on a case-by-case basis using the information described in this Interim Position Statement and the interim results from the PRINCIPLE trial (pre-print). This is an off-label use of a licensed medicine, the meaning of which should be discussed with the patient.

Note - If a budesonide inhaler is required then budesonide Easyhaler is the preferred product of choice.

➤ **[Chronic pain \(primary and secondary\) in over 16s: assessment of all chronic pain and management of chronic primary pain – guidance \(NG193\)](#)**

Guidance advises that chronic primary pain should be managed with exercise programmes, CBT, acceptance and commitment therapy, and acupuncture. The only drug treatments that should be considered are amitriptyline, citalopram, duloxetine, fluoxetine, paroxetine or sertraline.

➤ **Paravit CF**

Prescribers are reminded that Paravit CF products have been designated as 'Green' by NPAG for cystic fibrosis patients where recommended by a dietitian, cystic fibrosis consultant or the CG multidisciplinary team (which contains a dietitian).

➤ **Prescribing Inhixa brand of Enoxaparin**

Prescribers are reminded that enoxaparin should be prescribed by **brand** rather than generic name as delivery devices differ. **Inhixa** brand is the most cost effective in both primary and secondary care and is also the device that patients will have been shown how to use in secondary care.

➤ **Happy Retirement**

Sue Barron is retiring after many years of dutifully service to the CCG's Medicines Management Team. We wish the Sue the very best in her retirement and thank her for her significant contribution over the years. If you wish to sign her leaving card please click the link [card](#). A collection is being organised and if you would like to contribute please contact Paul Addison-Clarke directly [paul.addison-clarke@nhs.net](mailto:paul.addison-clarke@nhs.net)